2023年度

    Sekimodi T, Fukunaga K, Oizumi H, Baba T, Totsune T, Takeda A, Sasaki T, Kawahata I. FABP2 is Involved in Intestinal α-Synuclein Pathologies. J Integr Neurosci . 2024 Feb 22;23(2):44. doi: 10.31083/j.jin2302044.
    Kawahata I and Fukunaga K. Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets. Int. J. Mol. Sci. 2023 Dec 1;24(23):17037. doi: 10.3390/ijms242317037.
    Kawahata I, Sekimori T, Oizumi H, Takeda A, Fukunaga K. Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate Between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique. Int. J. Mol. Sci. 2023 Aug 26;24(17):13267. doi: 10.3390/ijms241713267.
    Cheng A, Jia W, Finkelstein DI, Stefanova N, Wang H, Sasaki T, Kawahata I, Fukunaga K. Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model. Acta Pharmacologica Sinica 2023 Aug 21. doi: 10.1038/s41401-023-01138-y.
    Sano, M., Fukunaga, K., Kawahata, I. Use of Melatonin in Caring for Dementia: Addressing Core Symptoms and Behavioral Challenges. J Clinical and Basic Psychosomatics 2023, 1(2), 1174. doi:10.36922/jcbp.1174.
    Cheng A, Kawahata I, Wang Y, Jia W, Haoyang W, Sekimori T, Chen Y, Suzuki H, Takeda A, Stefanova N, Finkelstein DI, Ma W, Chen M, Sasaki T, Fukunaga K. Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation. Brain. 2023 Apr 21:awad137. doi: 10.1093/brain/awad137
    Jia W, Kawahata I, Cheng A, Sasaki T, Sasaoka T, Fukunaga K. Amelioration of Nicotine-Induced Conditioned Place Preference Behaviors in Mice by an FABP3 Inhibitor. Int. J. Mol. Sci. 2023, 24(7), 6644. doi:10.3390/ijms24076644
    Kawahata I, Fukunaga K. Protein Kinases and Neurodegenerative Diseases. Int. J. Mol. Sci. 2023, 24(6), 5574. doi:10.3390/ijms24065574
    Wang H, Fukunaga K, Cheng A, Wang Y, Arimura N, Yoshino H, Sasaki T, Kawahata I. Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice. J Pharmacol Sci. 2023;152(1):30-38. 10.1016/j.jphs.2023.02.008
    Kawahata I, Fukunaga K. Endocytosis of dopamine receptor: Signaling in brain. Prog Mol Biol Transl Sci. 2023;196:99-111. doi: 10.1016/bs.pmbts.2022.09.005.
    Guo Q, Kawahata I, Jia W, Wang H, Cheng A, Yabuki Y, Shioda N, Fukunaga K. α-Synuclein decoy peptide protects mice against α-synuclein-induced memory loss. CNS Neurosci Ther. 2023 Feb 14. doi: 10.1111/cns.14120.
    Guo, Q.; Kawahata, I.; Cheng, A.; Jia, W.; Wang, H.; Fukunaga, K. Fatty Acid-Binding Proteins: Their Roles in Ischemic Stroke and Potential as Drug Targets. Int. J. Mol. Sci. 2022, 23, (23), 9648.
    Tagashira H, Bhuiyan MS, Shinoda Y, Kawahata I, Numata T, Fukunaga K. Sigma-1 receptor is involved in modification of ER-mitochondria proximity and Ca2+ homeostasis in cardiomyocytes. J Pharmacol Sci. 2023 Feb;151(2):128-133. doi: 10.1016/j.jphs.2022.12.005.
    Guo Q, Kawahata I, Cheng A, Wang H, Jia W, Yoshino H, Fukunaga K. Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons. Redox Biol. 2023 Feb;59:102547. doi: 10.1016/j.redox.2022.102547.
    Kawahata I., Fukunaga K., "Discovery of novel peptide therapeutics that can prevent synucleinopathy", Chemical Industry, January 2023. (Japanese)
    川畑 伊知郎, 武田 篤, 福永 浩司「特集：レビー小体病のバイオマーカー探索と早期予測技術の新展開 - レビー小体病の早期予測と鑑別技術の開発戦略」日本薬理学雑誌、2024 年 159 巻 1 号 p. 1-5 (Japanese) doi: 10.3390/ijms242317037.

2022年度

    Oizumi H., Sugimura Y., Tostune" T., Kawasaki I., Ohshiro S., Baba T., Kimpara T., Sakuma H., Hasegawa T., Kawahata I., Fukunaga K., Takeda A. Plasma sphingolipid abnormalities in neurodegenerative diseases. PLOS ONE 2022, in press.
    川畑 伊知郎, 福永 浩司, 「シヌクレイノパチーを予防可能な新規ペプチド治療薬の創製」, 化学工業, 2022年.
    Guo, Q., Kawahata, I., Cheng, A., Wang, H., Jia, W., Yoshino, H., Fukunaga, K. Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons. Redox Biology 2023(59), in press. doi:10.1016/j.redox.2022.102547
    Kawahata I, Fukunaga K. Endocytosis of dopamine receptor: Signaling in brain. Progress in Molecular Biology and Translational Science. 2022. doi:10.1016/bs.pmbts.2022.09.005
    Guo, Q.; Kawahata, I.; Cheng, A.; Jia, W.; Wang, H.; Fukunaga, K. Fatty Acid-Binding Proteins: Their Roles in Ischemic Stroke and Potential as Drug Targets. Int. J. Mol. Sci. 2022, 23, (23), 9648.
    Kawahata, I.; Finkelstein, D. I.; Fukunaga, K., Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in alpha-Synucleinopathies. Int. J. Mol. Sci. 2022, 23, (11), 6216.
    Kawahata I, Fukunaga K. Impact of fatty acid-binding proteins and dopamine receptors on α-synucleinopathy. J Pharmacol Sci. 2022 Feb;148(2):248-254. doi: 10.1016/j.jphs.2021.12.003. Epub 2021 Dec 14.
    川畑 伊知郎, 福永 浩司. αシヌクレインの伝播機序とレビー小体病の創薬戦略. 日本薬理学雑誌 2022, 157(6), 401~404.
    川畑 伊知郎, 福永 浩司. レビー小体病を予防可能な新規中分子治療薬の開発. 月刊BIOINDUSTRY 2022年1月号.

2021年度

    Cheng A, Jia W, Kawahata I, Fukunaga K. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models. EBioMedicine 2021 Vol. 72 Pages 103582. 10.1016/j.ebiom.2021.103582
    Kawahata I. Impact of dopamine D2 receptors in hyperkinesia and hyperpathia. Nihon Yakurigaku Zasshi. 2021;156(5):313. doi: 10.1254/fpj.21057.
    Xu J, Kawahata I, Izumi H, Fukunaga K. T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model. Int J Mol Sci. 2021 Jun 8;22(12):6185. doi: 10.3390/ijms22126185.
    Kawahata I. The novel mechanism of α-synuclein propagation in synucleinopathy. Nihon Yakurigaku Zasshi. 2021;156(4):251. doi: 10.1254/fpj.21033.
    Guo Q, Kawahata I, Degawa T, Ikeda-Matsuo Y, Sun M, Han F, Fukunaga K. Fatty Acid-Binding Proteins Aggravate Cerebral Ischemia-Reperfusion Injury in Mice. Biomedicines. 2021 May 10;9(5):529. doi: 10.3390/biomedicines9050529.
    Cheng A, Jia W, Kawahata I, Fukunaga K. Impact of Fatty Acid-Binding Proteins in α-Synuclein-Induced Mitochondrial Injury in Synucleinopathy. Biomedicines. 2021 May 17;9(5):560. doi: 10.3390/biomedicines9050560.
    Cheng A, Wang YF, Shinoda Y, Kawahata I, Yamamoto T, Jia WB, Yamamoto H, Mizobata T, Kawata Y, Fukunaga K. Fatty acid-binding protein 7 triggers α-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress. Acta Pharmacol Sin. 2021 May 2. doi: 10.1038/s41401-021-00675-8.
    Fukui N, Yamamoto H, Miyabe M, Aoyama Y, Hongo K, Mizobata T, Kawahata I, Yabuki Y, Shinoda Y, Fukunaga K, Kawata Y. An α-synuclein decoy peptide prevents cytotoxic α-synuclein aggregation caused by fatty acid binding protein 3. J Biol Chem. 2021 Apr 13:100663. doi: 10.1016/j.jbc.2021.100663.
    Degawa T, Kawahata I, Izumi H, Shinoda Y, Fukunaga K. T-type Ca2+ channel enhancer SAK3 administration improves the BPSD-like behaviors in AppNL-G-F/NL-G-F knock-in mice. J Pharmacol Sci. 2021 May;146(1):1-9. doi: 10.1016/j.jphs.2021.02.006.
    Jia W, Kawahata I, Cheng A, Fukunaga K. The Role of CaMKII and ERK Signaling in Addiction. Int J Mol Sci. 2021 Mar 20;22(6):3189. doi: 10.3390/ijms22063189.
    Kamagata K, Chiba R, Kawahata I, Iwaki N, Kanbayashi S, Maeda K, Takahashi H, Hirano A, Fukunaga K, Ikeda K, Kameda T. Characterization of design grammar of peptides for regulating liquid droplets and aggregates of FUS. Sci Rep. 2021 Mar 23;11(1):6643. doi: 10.1038/s41598-021-86098-1.
    Matsuo K, Kawahata I, Melki R, Bousset L, Owada Y, Fukunaga K. Suppression of α-synuclein propagation after intrastriatal injection in FABP3 null mice. Brain Res. 2021 Jun 1;1760:147383. doi: 10.1016/j.brainres.2021.147383.
    Wang Y, Shinoda Y, Cheng A, Kawahata I, Fukunaga K. Epidermal Fatty Acid-Binding Protein 5 (FABP5) Involvement in Alpha-Synuclein-Induced Mitochondrial Injury under Oxidative Stress. Biomedicines. 2021 Jan 22;9(2):110. doi: 10.3390/biomedicines9020110.
    Yuan D, Cheng A, Kawahata I, Izumi H, Xu J, Fukunaga K. Single Administration of the T-Type Calcium Channel Enhancer SAK3 Reduces Oxidative Stress and Improves Cognition in Olfactory Bulbectomized Mice. Int J Mol Sci. 2021 Jan 13;22(2):741. doi: 10.3390/ijms22020741.
    Kawahata I, Sekimori T, Wang H, Wang Y, Sasaoka T, Bousset L, Melki R, Mizobata T, Kawata Y, Fukunaga K. Dopamine D2 Long Receptors Are Critical for Caveolae-Mediated α-Synuclein Uptake in Cultured Dopaminergic Neurons. Biomedicines. 2021 Jan 8;9(1):49. doi: 10.3390/biomedicines9010049.
    川畑 伊知郎「アストロサイトにおけるαシヌクレインの新たな取り込み制御 」ファルマシア 57(10) 945-945 2021年10月
    川畑 伊知郎「ドパミンD2受容体の生理機能と運動・感覚障害」日本薬理学雑誌 156(5) 313-313 2021年9月
    川畑 伊知郎「シヌクレイノパチーにおけるαシヌクレインの新たな伝播機構 」日本薬理学雑誌 156(4) 251-251 2021年7月

2020年度

    Cheng A, Kawahata I, Fukunaga K. Fatty Acid Binding Protein 5 Mediates Cell Death by Psychosine Exposure through Mitochondrial Macropores Formation in Oligodendrocytes. Biomedicines. 2020 Dec 20;8(12):635. doi: 10.3390/biomedicines8120635.
    Jia W, Wilar G, Kawahata I, Cheng A, Fukunaga K. Impaired Acquisition of Nicotine-Induced Conditioned Place Preference in Fatty Acid-Binding Protein 3 Null Mice. Mol Neurobiol. 2021 May;58(5):2030-2045. doi: 10.1007/s12035-020-02228-2.
    Yabuki Y, Liu J, Kawahata I, Izumi H, Shinoda Y, Koga K, Ueno S, Shioda N, Fukunaga K. Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor. Int J Mol Sci. 2020 Aug 1;21(15):5525. doi: 10.3390/ijms21155525.
    Izumi H, Kawahata I, Shinoda Y, Helmstetter FJ, Fukunaga K. SAK3 Administration Improves Spine Abnormalities and Cognitive Deficits in AppNL-G-F/NL-G-F Knock-in Mice by Increasing Proteasome Activity through CaMKII/Rpt6 Signaling. Int J Mol Sci. 2020 May 28;21(11):3833. doi: 10.3390/ijms21113833.
    Kawahata I, Fukunaga K. Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease and Dopa-Responsive Dystonia. Int J Mol Sci. 2020 May 27;21(11):3779. doi: 10.3390/ijms21113779.
    Yabuki Y, Matsuo K, Kawahata I, Fukui N, Mizobata T, Kawata Y, Owada Y, Shioda N, Fukunaga K. Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain. Int J Mol Sci. 2020 Mar 23;21(6):2230. doi: 10.3390/ijms21062230.
    Haga H, Yamada R, Izumi H, Shinoda Y, Kawahata I, Miyachi H, Fukunaga K. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice. Pharmacol Biochem Behav. 2020 Apr;191:172891. doi: 10.1016/j.pbb.2020.172891. Epub 2020 Feb 29.
    Kawahata I, Bousset L, Melki R, Fukunaga K. Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons. Int J Mol Sci. 2019 Oct 28;20(21):5358. doi: 10.3390/ijms20215358.